Neurocrine Biosciences (NBIX) EBT Margin Growth (3y) (2013 - 2026)
Neurocrine Biosciences (NBIX) EBT Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 1,840.00 |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | -134.00 |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -5,626.00 |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | -1,686.00 |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -1,570.00 |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 5,487.00 |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -225.00 |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 3,138.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,487.00 |
| Dec 31, 2025 | 110.00 |
| Sep 30, 2025 | 1,147.00 |
| Jun 30, 2025 | 13,970.00 |
| Mar 31, 2025 | -432.00 |
| Dec 31, 2024 | 3,033.00 |
| Sep 30, 2024 | 2,029.00 |
| Jun 30, 2024 | -320.00 |
| Mar 31, 2024 | -480.00 |
| Dec 31, 2023 | 2,165.00 |
| Sep 30, 2023 | 4,526.00 |
| Jun 30, 2023 | -65.00 |
| Mar 31, 2023 | -4,098.00 |
| Dec 31, 2022 | 1,280.00 |
| Sep 30, 2022 | -106.00 |
| Jun 30, 2022 | -14,489.00 |
| Mar 31, 2022 | 8,102.00 |
| Dec 31, 2021 | -1,870.00 |
| Sep 30, 2021 | -2,315.00 |
| Jun 30, 2021 | 2,600.00 |